MEA Digital PCR and Real Time PCR (qPCR) Market

MEA Digital PCR and Real-Time PCR (qPCR) Market Size (2023 to 2028)

The size of the Middle East & Africa Digital PCR and Real-Time PCR (qPCR) market accounted for USD 426.68 million in 2023. It is expected to grow at 8.966% CAGR and is predicted to be around USD 655.30 million in 2028.

The demand for genomic analysis techniques has grown steadily over the past decade due to their increasing use in diagnosing major infectious diseases (such as HIV, tuberculosis, malaria, and hepatitis) and genetic disorders (such as cancer). For example, according to UNAIDS, approximately 39.6 million people lived with HIV / AIDS worldwide, with an average mortality of 0.69 million. Of these, 1.75 million new cases of HIV infection were reported in 2019 alone. Additionally, according to WHO, around 10.5 million new tuberculosis cases were recorded worldwide in 2019, and 238 million patients suffered from malaria worldwide in 2019, and 92.3% of cases were recorded in the African region alone.

The growing prevalence of target diseases worldwide, coupled with the proven effectiveness of qPCR and dPCR tests in the diagnosis and estimation of pathogenic microbes, will stimulate the use of clinical diagnostic tests (including the qPCR test and dPCR) and will support growth.

Emerging markets are expected to offer significant growth opportunities due to the increasing incidence of infectious and chronic diseases and increased R&D efforts to develop innovative PCR techniques such as qPCR and dPCR. In addition, expanding healthcare infrastructure, increasing healthcare spending, and reducing the costs of diagnostic procedures based on qPCR and dPCR help market growth. Emerging countries are experiencing rapid modernization of health facilities and an expansion of health infrastructure. This factor contributes to the growing demand for clinical diagnostic procedures among diagnostic laboratories, leading to increased clinical qPCR and dPCR products.

A typical PCR analysis performed using dPCR instruments involves several scientific technologies (PCR, microfluidics, and nanofabrication) integrated to achieve the desired result. These instruments are small and have short cycle times. However, the development of such instruments requires high investments and in-depth scientific validation at a deeper level. The high prices have led to moderate adoption of dPCR instruments among price-sensitive end-users. Additionally, demand for expensive dPCR instruments is limited due to consumer preference for cheaper genomic techniques (such as gel electrophoresis and traditional PCR), especially among researchers and small CROs, and pharmaceutical and biotechnology companies.

Currently, qPCR and dPCR techniques are not regulated worldwide, which has made consumers reluctant to use qPCR and dPCR products in genomic analysis and disease diagnosis. This is due to irregular gradients that exist for how qPCR / dPCR experiments ought to be performed to obtain true quality results within a given time frame. These shortcomings have challenged market growth.

This research report on the Middle East and Africa Digital PCR and Real-time PCR Market has been segmented and sub-segmented into the following categories:

By Product: 

• Consumables
• Reagents and Instruments

By Technology: 

• Quantitative PCR
• Digital PCR

By Application: 

• Tumors
• Blood Testing
• Pathogen Detection
• Research & Forensics

By End User: 

• Hospitals
• Research & Forensic Centers
• Pharmaceutical & Bio-Technological Firms
• Academic Institutions

By Country: 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, Middle East is expected to dominate the qPCR and dPCR, followed by Africa in the MEA region. The Middle East qPCR and dPCR market will be driven by the increased adoption of innovative genomic analysis products, the availability of R&D funds for the developments, the use of PCR techniques in clinical and forensic diagnostics, and early commercialization of qPCR / dPCR products relative to other regions.

KEY MARKET PARTICIPANTS:

Thermo Fisher Scientific Inc., F Hoffman-La Roche Ltd., Bio-Rad Laboratories, Qiagen N.V., Taraka Bio Inc., Affymetrix Inc., Agilent Technologies Inc., Fluidigm Corporation, Danaher Corporation, and Becton & Dickson Company are a few of the leading companies in the MEA Digital PCR and Real-time PCR Market.